Alpha-synuclein is a presynaptic neuronal protein widely expressed in the brain that regulates synaptic vesicle trafficking and subsequent neurotransmitter release. It is abundant in the brain and less abundant in the heart, muscle and other tissues. In the brain, α-synuclein is mainly present at the axon terminals of presynaptic neurons. Among these terminals, α-synuclein interacts with phospholipids and proteins. Alpha-synuclein is genetically and neuropathologically implicated in Parkinson's disease (PD), Alzheimer's disease (AD). Alpha-synuclein may contribute to disease pathogenesis in several ways, but its abnormal soluble oligomeric conformation (called fibrils) is generally thought to mediate disruption of cellular homeostasis and toxic substances in neuronal death, including synaptophysin. touch function. In addition, secreted α-synuclein may have deleterious effects on neighboring cells, including the seeding of aggregates, which may lead to disease transmission.
Comprehensive target analysis enables our experts to employ optimal hit discovery strategies and ultimately design better selective compounds.
Small molecules can be designed based on protein targets, reference molecules, or even protein sequences. We will create a generative model of a molecule by placing atoms in 3D space. These are more realistic and can yield better predictions than alternative methods based on molecular maps. Our model will guarantee that the generated molecules can be synthesized in advance.
Molecules are screened by various methods, such as AI-based docking, free energy, ADMET prediction, etc. Molecules in patents will also be filtered.
With our technology, many properties of molecule (molecular energy, toxicity, activity) can be predicted.
Computational drug discovery services or CADD services cover all stages of preclinical drug discovery, leveraging a wide range of technologies such as target identification services, HIT discovery services, lead optimization services, drug repurposing services, and more. We use techniques such as high-throughput screening, molecular modeling, analog design, structural biology, molecular docking and computational chemistry to determine the binding affinity and appropriate targeting of compounds. We have expertise in the field of neurodegenerative disease treatment, to say the least.